NR 293
Nurtec ODT (Rimegepant)
Chamberlain College of Nursing
NR 293 – Pharmacology
Rimegepant (Nurtec ODT) is a medication that was first approved by the FDA on
February 27, 2020, to be used as a treatment for acute migraines (National Center for
Biotechnology Information, 2020). Rimegepant is a calcitonin gene-related peptide receptor
antagonist (CGRP), which is also referred to as gepants. Nurtec is the first CGRP to come in an
orally disintegrating tablet but has drug interactions with CYP3A4 inhibitors, CYP3A inducers,
and transporters. Rimegepant offers migraine relief to an expanded population when compared to
triptans. Triptans constrict the blood vessels, which leaves a possibility for coronary artery
construction as well. Since Nurtec does not have these properties, patients with hypertension or
other heart-related problems are not contraindicated in this medication (Lipton, et al., 2020).
Nurtec should be avoided in pregnant, breastfeeding patients or plan on becoming
pregnant, the elderly, and children as there have not been enough clinical trials to show how it
affects these individuals (Biohaven Pharmaceuticals, 2020). Nurtec is contraindicated in patients
with liver impairment, end-stage renal disease, and hypersensitivity to any drug components
(Biohaven Pharmaceuticals, 2020). This brochure should be used to give information to possible
patients or patients who have recently been prescribed the medication. In addition, this brochure
should also be shown to healthcare professionals or caregivers to understand how to administer
the medication and properly inform/educate the client.
Nurtec ODT (Rimegepant)
Chamberlain College of Nursing
NR 293 – Pharmacology
Rimegepant (Nurtec ODT) is a medication that was first approved by the FDA on
February 27, 2020, to be used as a treatment for acute migraines (National Center for
Biotechnology Information, 2020). Rimegepant is a calcitonin gene-related peptide receptor
antagonist (CGRP), which is also referred to as gepants. Nurtec is the first CGRP to come in an
orally disintegrating tablet but has drug interactions with CYP3A4 inhibitors, CYP3A inducers,
and transporters. Rimegepant offers migraine relief to an expanded population when compared to
triptans. Triptans constrict the blood vessels, which leaves a possibility for coronary artery
construction as well. Since Nurtec does not have these properties, patients with hypertension or
other heart-related problems are not contraindicated in this medication (Lipton, et al., 2020).
Nurtec should be avoided in pregnant, breastfeeding patients or plan on becoming
pregnant, the elderly, and children as there have not been enough clinical trials to show how it
affects these individuals (Biohaven Pharmaceuticals, 2020). Nurtec is contraindicated in patients
with liver impairment, end-stage renal disease, and hypersensitivity to any drug components
(Biohaven Pharmaceuticals, 2020). This brochure should be used to give information to possible
patients or patients who have recently been prescribed the medication. In addition, this brochure
should also be shown to healthcare professionals or caregivers to understand how to administer
the medication and properly inform/educate the client.
